Search Results for "Hydrocodone Bitartrate 7 5 Mg"

12:00 EST 22nd December 2014 | BioPortfolio

Matching Channels

None

Matching News

FDA grants Priority Review designation for Purdue’s hydrocodone bitartrate

Privately held US drugmaker Purdue Pharma has been granted Priority Review designation by the US Food and Drug Administration for its once-daily, single-entity hydrocodone bitartrate tablet.

Purdue gets FDA priority review designation for hydrocodone bitartrate tablets

The US Food and Drug Administration (FDA) has granted priority review designation for US-based Purdue Pharma's hydrocodone bitartrate extended-release tablets for treatment of chronic pain.

Purdue’s hydrocodone bitartrate tablets granted priority review designation

Purdue Pharma has been granted priority review designation by the US Food and Drug Administration (FDA) for its hydrocodone bitartrate extended-release tablets for treatment of chronic pain.

Update on Tamper-Proof Hydrocodone Products

Purdue and Zogenix report their progress in gaining approval for formulations of single-entity hydrocodone bitartrate that are difficult to misuse or abuse. Medscape Medical News

Vycavert hydrocodone bitartrate/acetaminophen regulatory update

Mallinckrodt Pharmaceuticals Releases Human Abuse Liability (HAL) Data for Investigational MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination

HAL study compared subjective effects of drug liking, drug high and good drug effects between MNK-155 and an immediate-release hydrocodone bitartrate/acetaminophen formulation in ...

Priority Review for Purdue’s anti-abuse hydrocodone

The US FDA has granted Priority Review Designation to Purdue Pharma’s hydrocodone bitartrate tablet which has abuse-deterrent technology.

FDA Approves Hysingla ER - Extended-Release Hydrocodone with Abuse-Deterrent Properties

November 20, 2014 -- The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, ...

Matching PubMed Articles

Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.

Infantile neuronal ceroid lipofuscinosis is a devastating neurodegenerative lysosomal storage disease caused by mutations in the gene (CLN1 or PPT1) encoding palmitoyl-protein thioesterase-1 (PPT1). W...

DEA Tightens Restrictions on Hydrocodone Combination Products.

Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.

Abstract Background: Hydrocodone/acetaminophen combination analgesics are frequently prescribed for chronic pain management; however, acetaminophen presents potential hepatotoxicity to patients and th...

Rescheduling of hydrocodone combination products.

Extended-release hydrocodone (Zohydro) for pain.

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement